BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 31154393)

  • 1.
    Collet L; Ghurburrun E; Meyers N; Assi M; Pirlot B; Leclercq IA; Couvelard A; Komuta M; Cros J; Demetter P; Lemaigre FP; Borbath I; Jacquemin P
    Gut; 2020 Apr; 69(4):704-714. PubMed ID: 31154393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
    Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
    Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms.
    Oyama H; Tada M; Takagi K; Tateishi K; Hamada T; Nakai Y; Hakuta R; Ijichi H; Ishigaki K; Kanai S; Kogure H; Mizuno S; Saito K; Saito T; Sato T; Suzuki T; Takahara N; Morishita Y; Arita J; Hasegawa K; Tanaka M; Fukayama M; Koike K
    Gastroenterology; 2020 Jan; 158(1):226-237.e5. PubMed ID: 31473224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanism of intraductal papillary mucinous neoplasm and intraductal papillary mucinous neoplasm-derived pancreatic ductal adenocarcinoma.
    Fukuda A
    J Hepatobiliary Pancreat Sci; 2015 Jul; 22(7):519-23. PubMed ID: 25900667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GNAS(R201H) and Kras(G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm.
    Taki K; Ohmuraya M; Tanji E; Komatsu H; Hashimoto D; Semba K; Araki K; Kawaguchi Y; Baba H; Furukawa T
    Oncogene; 2016 May; 35(18):2407-12. PubMed ID: 26257060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
    Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
    J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraductal papillary mucinous neoplasms of the pancreas: Clinical association with KRAS.
    Chang XY; Wu Y; Li Y; Wang J; Chen J
    Mol Med Rep; 2018 Jun; 17(6):8061-8068. PubMed ID: 29658583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic medullary carcinoma developed on a pancreatic intraductal papillary mucinous neoplasm with loss of MSH2 and MSH6 expression: a case report.
    Verocq C; Racu ML; Bafort D; Butorano G; Perez-Casanova Garcia L; Navez J; Witterwulghe M; Sheahan K; Swan N; Closset J; Van Laethem JL; Maris C; D'Haene N
    Diagn Pathol; 2021 Dec; 16(1):117. PubMed ID: 34895278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
    Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
    Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficient Rnf43 potentiates hyperactive Kras-mediated pancreatic preneoplasia initiation and malignant transformation.
    Zhou X; Sun Z; Zhang M; Qu X; Yang S; Wang L; Jing Y; Li L; Deng W; Liu F; Di J; Chen J; Wu J; Zhang H
    Animal Model Exp Med; 2022 Feb; 5(1):61-71. PubMed ID: 35229994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic DCLK1
    Qiu W; Remotti HE; Tang SM; Wang E; Dobberteen L; Lee Youssof A; Lee JH; Cheung EC; Su GH
    Cancer Lett; 2018 Jun; 423():71-79. PubMed ID: 29526803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
    Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
    J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraductal Papillary Mucinous Carcinoma Versus Conventional Pancreatic Ductal Adenocarcinoma: A Comprehensive Review of Clinical-Pathological Features, Outcomes, and Molecular Insights.
    Mas L; Lupinacci RM; Cros J; Bachet JB; Coulet F; Svrcek M
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression.
    Mohri D; Asaoka Y; Ijichi H; Miyabayashi K; Kudo Y; Seto M; Ohta M; Tada M; Tanaka Y; Ikenoue T; Tateishi K; Isayama H; Kanai F; Fukushima N; Tada M; Kawabe T; Omata M; Koike K
    J Gastroenterol; 2012 Feb; 47(2):203-13. PubMed ID: 22041919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms.
    Huang B; Trujillo MA; Fujikura K; Qiu M; Chen F; Felsenstein M; Zhou C; Skaro M; Gauthier C; Macgregor-Das A; Hutchings D; Hong SM; Hruban RH; Eshleman JR; Thompson ED; Klein AP; Goggins M; Wood LD; Roberts NJ
    J Pathol; 2020 Nov; 252(3):252-262. PubMed ID: 32696980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of Trefoil Factor 2 From Pancreatic Duct Glands Promotes Formation of Intraductal Papillary Mucinous Neoplasms in Mice.
    Yamaguchi J; Mino-Kenudson M; Liss AS; Chowdhury S; Wang TC; Fernández-Del Castillo C; Lillemoe KD; Warshaw AL; Thayer SP
    Gastroenterology; 2016 Dec; 151(6):1232-1244.e10. PubMed ID: 27523981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tracking the Clonal Evolution of Adenosquamous Carcinoma, a Rare Variant of Intraductal Papillary Mucinous Neoplasm of the Pancreas.
    Matsuzaka S; Karasaki H; Ono Y; Ogata M; Oikawa K; Tamakawa S; Chiba S; Muraki M; Yokochi T; Funakoshi H; Kono T; Nagashima K; Mizukami Y
    Pancreas; 2016 Jul; 45(6):915-8. PubMed ID: 27295533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
    Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
    Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice.
    Shibata W; Kinoshita H; Hikiba Y; Sato T; Ishii Y; Sue S; Sugimori M; Suzuki N; Sakitani K; Ijichi H; Mori R; Endo I; Maeda S
    Sci Rep; 2018 Apr; 8(1):6150. PubMed ID: 29670173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.